{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=15",
    "query": {
      "intervention": "EPOCH II",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 887,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T19:28:35.377Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03721107",
      "title": "A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Blautix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "4D pharma plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 366,
      "start_date": "2018-10-11",
      "completion_date": "2020-05-13",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03721107"
    },
    {
      "nct_id": "NCT00203411",
      "title": "Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine (Xeloda)",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Translational Oncology Research International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2006-03",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-02-06",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 12,
      "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 9 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00203411"
    },
    {
      "nct_id": "NCT03390933",
      "title": "Identifying and Treating Depression in Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Hemodialysis-Induced Symptom"
      ],
      "interventions": [
        {
          "name": "Fluoxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-03-01",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03390933"
    },
    {
      "nct_id": "NCT00505271",
      "title": "Safety and Efficacy Study Using Rexin-G for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Rexin-G",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Epeius Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-07",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-06-10",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 3,
      "location_summary": "San Marino, California • Santa Monica, California • New York, New York",
      "locations": [
        {
          "city": "San Marino",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505271"
    },
    {
      "nct_id": "NCT07392957",
      "title": "Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "CTX-009",
          "type": "DRUG"
        },
        {
          "name": "CTX-471",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2026-06-16",
      "completion_date": "2031-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07392957"
    },
    {
      "nct_id": "NCT04179721",
      "title": "Reducing Behavioral and Psychological Symptoms of Dementia: Hospital Caregivers (Aim 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease and Related Dementias"
      ],
      "interventions": [
        {
          "name": "PES-4-BPSD Model",
          "type": "BEHAVIORAL"
        },
        {
          "name": "The attention control condition",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2019-10-22",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 2,
      "location_summary": "Glen Oaks, New York • Manhasset, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179721"
    },
    {
      "nct_id": "NCT04292535",
      "title": "Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin",
        "Exercise"
      ],
      "interventions": [
        {
          "name": "Placebo into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "20 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "40 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "60 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "80 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "100 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "120 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-06-15",
      "completion_date": "2020-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 1,
      "location_summary": "East Lansing, Michigan",
      "locations": [
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04292535"
    },
    {
      "nct_id": "NCT05428007",
      "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab/Relatlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-02-02",
      "completion_date": "2028-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05428007"
    },
    {
      "nct_id": "NCT02138825",
      "title": "Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary"
      ],
      "interventions": [
        {
          "name": "Riociguat (Adempas, BAY63-2521)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 147,
      "start_date": "2014-06-04",
      "completion_date": "2016-09-14",
      "has_results": true,
      "last_update_posted_date": "2017-12-04",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138825"
    },
    {
      "nct_id": "NCT00440609",
      "title": "Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinically Significant Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip J. ferrone, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-11-15T19:28:35.377Z",
      "location_count": 2,
      "location_summary": "Great Neck, New York • Hauppauge, New York",
      "locations": [
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Hauppauge",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440609"
    }
  ]
}